Home › Companies › COGT

Cogent Biosciences

COGT Rare disease Lead: NDA Submitted ★ Read the deep dive → 4 Biotech Distilled articles ↓

Hematology Oncology Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (6 active programs)

bezuclastinib

CGT9486

Small Molecule Target: KIT D816V, KIT exon 17, KIT

Non-Advanced Systemic Mastocytosis NDA Submitted oral Plexxikon
Gastrointestinal Stromal Tumor NDA Submitted oral Plexxikon

CGT4859

Small Molecule Target: FGFR2, FGFR3

Cholangiocarcinoma Phase 1 oral

CGT4255

Small Molecule Target: ErbB2, HER2

Advanced Solid Tumors Phase 1 oral

CGT6297

Small Molecule Target: PI3Kα

Advanced Solid Tumors Phase 1

CGT1145

Small Molecule Target: JAK2 V617F

Undisclosed indication Preclinical oral

Biotech Distilled coverage (4)

2026-06-12 UPDATE: Cogent Biosciences (COGT) - APEX Goes Deep, and the Third Pivotal Lands Clean
2026-06-02 UPDATE: Cogent Biosciences (COGT) - PEAK Goes Under the Microscope, and a 1L Shot Opens Up 🔒 Paid
2026-05-28 UPDATE: Cogent Biosciences (COGT) - The GIST Clock is Set, ASCO is Saturday 🔒 Paid
2026-04-18 Cogent Biosciences (COGT) - Scientific Deep Dive for Bezuclastlnib and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.